John Libbey Eurotext

European Journal of Dermatology

MENU

A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma Volume 28, numéro 1, January-February 2018

Illustrations

  • Figure 1

Tableaux

Auteurs
1 Department of Dermatology, CHRU, Tours, France
2 PRES Centre, Val de Loire University, University Francois Rabelais de Tours, Tours, France
3 Department of Dermatology, CHR Le Mans, France
4 Department of Dermatology, CHR Orléans, France
5 INSERM CIC 1415, CHRU Tours, France
6 Inserm U 930, University Francois Rabelais, Tours, France
* Reprints
  • Mots-clés : neutrophil/lymphocyte ratio, BRAF, prognostic factor, corticosteroid, progression-free survival, melanoma
  • DOI : 10.1684/ejd.2017.3167
  • Page(s) : 38-43
  • Année de parution : 2018

Background

Some studies have shown that a high neutrophil/lymphocyte ratio (NLR) ≥4 before initiating ipilimumab treatment is an independent prognostic indicator of poor survival in patients with metastatic melanoma (MM).